Herve Jacquiau, Ph.D. co-authored this article on the diverse effects on SUMO conjugation, induced by defects in Ubc9 or a SUMO specific protease, alter the cytotoxic consequences of Top1 activity. DNA topoisomerase I (Top1) constitutes the cellular target of camptothecin (CPT), which stabilizes a covalent Top1-DNA intermediate. During S-phase the CPT-Top1-DNA complexes are converted into lethal lesions that induce cell cycle arrest and cell death. To define cellular processes that protect cells from CPT-induced lesions, conditional mutants with enhanced sensitivity to Top1 poisons were isolated in yeast genetic screens.
Hervé Jacquiau, Ph.D., assists in all aspects of patent practice, including patent prosecution and litigation. His background covers a variety of technologies, particularly biotechnology, bioengineering, biochemistry, molecular biology and microbiology. Hervé received his Ph.D. degree from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants.
To read the article abstract, please click the link below:
